Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Sponsor
The Queen Elizabeth Hospital
Study ID
NCT01139138
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Panitumumab — DRUG
    Panitumumab 6mg/kg IV every 14 days
  • Irinotecan — DRUG
    Irinotecan 200mg/m2 IV every 14 days
  • Everolimus — DRUG
    Everolimus daily po (dosage varies with cohort)

Study Details

This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer

Key Dates

Start date
Jun 30, 2010
Status verified
Nov 2017
Primary completion
Aug 31, 2015
Completion
Jun 30, 2017

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Panitumumab + Irinotecan + Everolimus

Primary Outcome Measure

Dose limiting toxicities [ Time Frame: at end of cycle 2 (each cycle is 14 days) ]

Related Studies